Marlborough, MA, United States of America

Patrick Koch

USPTO Granted Patents = 11 (Patent Applications = 1)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 6.6

ph-index = 2

Forward Citations = 45(Granted Patents)

Company Filing History:

6 out of 130

Sunovion Pharmaceuticals Inc.

Years Active: 1999-2020

Loading Chart...

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10562878 - Cycloalkylamines as monoamine reuptake inhibitors (2020-02-18),

2. 9868718 - Cycloalkylamines as monoamine reuptake inhibitors (2018-01-16),

3. 9586888 - Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors (2017-03-07),

4. 8877975 - Cycloalkylamines as monoamine reuptake inhibitors (2014-11-04),

5. 8669291 - Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors (2014-03-11),

6. 8053603 - Tetralone-based monoamine reuptake inhibitors (2011-11-08),

7. 6455530 - 2R,4S,S,S- and 2S,4R,S,S-hydroxyitraconazole (2002-09-24),

8. 6174902 - R-rabeprazole compositions and methods (2001-01-16),

9. 6166018 - 2R, 4S, R, S- and 2S, 4R, R, S-hydroxyitraconazole (2000-12-26),

10. 6147077 - 2R,4S-hydroxyitraconazole isomers (2000-11-14),

11. 5952502 - 2R,4S,R, S- and 2S,4R,R,S-hydroxyitraconazole (1999-09-14),

Title: The Innovative Contributions of Patrick Koch

Introduction

Patrick Koch is a notable inventor based in Marlborough, MA (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 11 patents to his name, Koch has made strides in developing novel compounds aimed at treating various central nervous system (CNS) disorders.

Latest Patents

Among his latest patents, Koch has developed cycloalkylamines as monoamine reuptake inhibitors. This invention focuses on novel cyclohexylamine derivatives and their application in treating and preventing CNS disorders such as depression, anxiety, schizophrenia, and sleep disorders. The patent also details methods for synthesizing these compounds, along with pharmaceutical compositions that incorporate them. Furthermore, it outlines methods for inhibiting the reuptake of endogenous monoamines, including dopamine, serotonin, and norepinephrine from the synaptic cleft, as well as techniques for modulating one or more monoamine transporters.

Career Highlights

Throughout his career, Patrick Koch has worked with prominent companies in the pharmaceutical industry, including Sunovion Pharmaceuticals Inc. and Sepracor, Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Koch has collaborated with notable colleagues such as Liming Shao and Fengjiang Wang, further enhancing his research and development efforts in the pharmaceutical sector.

Conclusion

Patrick Koch's innovative work in developing treatments for CNS disorders showcases his dedication to improving mental health through scientific advancements. His contributions continue to impact the field of pharmaceuticals positively.

This text is generated by artificial intelligence and may not be accurate.